Over the last few decades, immune checkpoint inhibitors (ICIs) against programmed death receptor 1 (PD-1), programmed death receptor ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have emerged as a revolutionary option for cancer treatment. This evidence concerns the gene CTLA4 and cancer.